Graybug Vision, Inc. (NASDAQ:GRAY – Get Free Report) shares traded down 3.3% during trading on Friday . The stock traded as low as $2.01 and last traded at $2.04. 35,965 shares changed hands during mid-day trading, an increase of 1,561% from the average session volume of 2,165 shares. The stock had previously closed at $2.11.
Graybug Vision Trading Down 4.3 %
The company has a market cap of $3.16 million, a price-to-earnings ratio of -1.16 and a beta of 1.20. The firm has a 50-day moving average price of $2.50 and a 200 day moving average price of $3.28.
Graybug Vision Company Profile
Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.
Featured Stories
- Five stocks we like better than Graybug Vision
- Health Care Stocks Explained: Why You Might Want to Invest
- AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
- Manufacturing Stocks Investing
- 3 ETFs to Ride the VIX Surge During Market Volatility
- How Can Investors Benefit From After-Hours Trading
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
